Renovaro Inc.

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
1.32 ^USD	+40.43%		+43.90%	-58.36%

04-24	Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	MT
04-18	Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	CI

Enochian Biosciences, Inc. Announces Resignation of Carl Sandler as Member of the Board of Directors

March 29, 2022 at 06:12 am

On March 25, 2022, Carl Sandler provided notice of his resignation as a member of the Board of Directors of Enochian Biosciences Inc. to focus on his other business ventures, with such resignation being effective March 25, 2022.

Latest news about Renovaro Inc.

Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	04-24	MT
Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	04-18	CI
Renovaro Inc. Appoints Simon Tarsh as Interim Chief Financial Officer	03-13	CI
Renovaro Inc. Announces Resignation of Luisa Puche as Chief Financial Officer, Effective as of March 21, 2024	03-05	CI
Renovaro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-14	CI
Renovaro Inc. Announces Board Changes	02-14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	02-14	MT
Sector Update: Health Care	02-14	MT
Renovaro Shares Jump After Response to Short Seller Hindenburg's Report	02-14	MT
Sector Update: Health Care Stocks Decline Late Afternoon	02-13	MT
Renovaro's GEDi Cube Agrees to Acquire 75% Stake in Cyclomics	02-13	MT
Renovaro Shares Tumble Following Report From Short-Seller Hindenburg	02-13	MT
Renovaro Biosciences Inc. completed the acquisition of GEDi Cube Intl Ltd. for $59.2 million.	02-12	CI
Top Premarket Gainers	02-07	MT
Renovaro Biosciences' Shareholders Approve Share Issuance for Merger Deal With GEDi Cube	01-25	MT
North American Morning Briefing : Stock Futures -2-	11-16	DJ
Renovaro Biosciences Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors	23-10-11	CI
Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors	23-10-10	CI
North American Morning Briefing : Stock Futures, -2-	23-10-05	DJ
Renovaro Biosciences Inc. announced that it expects to receive $2 million in funding	23-10-04	CI
Renovaro Biosciences Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-02	CI
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT
Renovaro Biosciences, GEDi Cube Enter Stock-for-stock Acquisition Deal	23-09-29	MT
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ

Chart Renovaro Inc.

Duration

Period

More charts

Company Profile

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVARO INC.	-58.36%	139M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs